Physician profile
Stephanie Vertrees
NPI 1194941211
$119,326.48
in general payments reported to CMS, 2019-2025
23 companies · $33K in 2025
The $33K reported for 2025 was more than what 95% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $21K · 2021: $33K · 2022: $13K · 2023: $7,148 · 2024: $12K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $34K · Consulting Fee: $11K · Food and Beverage: $5,011 · Travel and Lodging: $2,266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,005.00 |
| Consulting Fee | $10,610.23 |
| Food and Beverage | $5,010.66 |
| Travel and Lodging | $2,265.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $39,061.77 | 2023-2025 | |
| Abbvie INC. | $34,749.00 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Lilly USA, LLC | $26,447.43 | 2019-2025 | Emgality, Reyvow, Kisunla |
| Amgen INC. | $10,335.44 | 2019-2023 | Aimovig |
| Lundbeck LLC | $4,590.25 | 2021-2025 | Vyepti |
| Allergan, INC. | $2,257.99 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $483.10 | 2021-2025 | Ajovy, Austedo Xr |
| Biohaven Pharmaceutical Holding Company Ltd. | $381.15 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $187.98 | 2021 | |
| Axsome Therapeutics, INC. | $156.89 | 2025 | Symbravo |
| Novartis Pharmaceuticals Corporation | $115.05 | 2019-2021 | |
| Tonix Medicines, INC. | $114.41 | 2024 | Zembrace Symtouch |
| Eli Lilly and Company | $87.47 | 2024 | Emgality |
| Impel Pharmaceuticals LLC | $71.32 | 2024-2025 | Trudhesa |
| Upsher-Smith Laboratories LLC | $70.25 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $47.40 | 2023-2024 | Dysport |
| Revance Therapeutics, INC. | $35.20 | 2025 | Daxxify |
| Merz Pharmaceuticals, LLC | $28.48 | 2023 | Xeomin |
| Collegium Pharmaceutical, INC. | $25.10 | 2022 | |
| Impel Pharmaceuticals INC. | $24.73 | 2023 | Trudhesa |
| Amneal Pharmaceuticals LLC | $21.20 | 2025 | Brekiya |
| Abbott Laboratories | $17.50 | 2024 | Proclaim |
| Currax Pharmaceuticals LLC | $17.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Vertrees listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.